Recent blog posts
CanSino's Herpes Zoster vaccine CS-2032 has been approved for clinical use in Canada
Latest Hotspot
2 min read
CanSino's Herpes Zoster vaccine CS-2032 has been approved for clinical use in Canada
26 July 2023
On July 23, CanSino Biologics announced that its recombinant shingles vaccine CS-2032, developed in collaboration with Vaccitech, has received clinical trial approval from Health Canada.
Read →
Roche introduces Alnylam's hypertension RNAi therapy, Zilebesiran, with a potential transaction value of up to 2.8 billion dollars
Latest Hotspot
3 min read
Roche introduces Alnylam's hypertension RNAi therapy, Zilebesiran, with a potential transaction value of up to 2.8 billion dollars
26 July 2023
On July 24, 2023, Alnylam announced that it has reached a strategic agreement with Roche to develop and commercialize Zilebesiran, Alnylam's RNAi therapeutic drug for the treatment of hypertension.
Read →